Are you Dr. Raghav?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 31 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Summary
- Dr. Kanwal Raghav, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Arizona, and Washington. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 2006 - 2009
Delhi University College of Medical SciencesClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2024 - 2026
TN State Medical License 2024 - 2026
OK State Medical License 2020 - 2025
WA State Medical License 2024 - 2025
TX State Medical License 2010 - 2025
GA State Medical License 2024 - 2025- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors Start of enrollment: 2017 Apr 07
- S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery Start of enrollment: 2017 Nov 27
- Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer Start of enrollment: 2019 Jan 29
Publications & Presentations
PubMed
- Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling.Wang, X., Dasari, A., Shen, J., Drusbosky, L., Johnson, B., Morris, V., Raghav, K., Lee, M., Huey, R., Parseghian, C., Willis, J., Wolff, R., Overman, M., Kopetz, S.> ;Cancers. 2024 Feb 9
- Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma.Abdelrahman Yousef, Mahmoud Yousef, Mohammad A Zeineddine, Aditya More, Mohammad Fanaeian, Saikat Chowdhury, Mark Knafl, Paul Edelkamp, Ichiaki Ito, Yue Gu, Vinay Patt...> ;JAMA Network Open. 2024 Feb 5
- Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination.Simmons, K., Thomas, J., Ludford, K., Willis, J., Higbie, V., Raghav, K., Johnson, B., Dasari, A., Kee, B., Parseghian, C., Lee, M., Le, P., Morelli, M., Shen, J., Ben...> ;Cancer Research Communications. 2023 Dec 11
- Join now to see all
Press Mentions
MD Anderson Research Highlights: ASCO 2023 Special EditionMay 25th, 2023- Most Cancers of the Unknown Main Survivor: Why I Joined a Scientific Trial at MD AndersonSeptember 23rd, 2022
- Cancer of the Unknown Primary Survivor: Why I Joined a Clinical Trial at MD AndersonSeptember 23rd, 2022
- Join now to see all
Hospital Affiliations
University of Texas M.D. Anderson Cancer CenterHouston, Texas
